SuperworthCRISPR Therapeutics revenue CRSP
Sales by quarter and over the last twelve months, from 2016.
- Last 12 months, to Jun 30, 2026
- $13.4M
- Latest quarter, Q2 FY26
- $10.2M
- +1041% on a year earlier
- Fiscal year 2025
- $3.5M
- −91% on the year before
CRISPR Therapeutics' revenue was $13.4M over the twelve months to Jun 30, 2026, down 65% on a year earlier.
In its latest quarter, Q2 FY26, it was $10.2M, up 1041% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 37% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $3.5M | −91% |
| FY2024 | $37.3M | −90% |
| FY2023 | $371.2M | +30885% |
| FY2022 | $1.2M | −100% |
| FY2021 | $915M | +127155% |
| FY2020 | $719K | −100% |
| FY2019 | $289.6M | +9170% |
| FY2018 | $3.1M | −92% |
| FY2017 | $41M | +694% |
| FY2016 | $5.2M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $10.2M | +1041% | $13.4M | |
| Q1 FY26 | $1.5M | +69% | $4.1M | |
| Q4 FY25 | $864K | −98% | $3.5M | |
| Q3 FY25 | $889K | +48% | $38.3M | |
| Q2 FY25 | $892K | +73% | $38M | |
| Q1 FY25 | $865K | +72% | $37.7M | |
| Q4 FY24 | $35.7M | −82% | $37.3M | |
| Q3 FY24 | $602K | n/a | $202.8M | |
| Q2 FY24 | $517K | −99% | $202.2M | |
| Q1 FY24 | $504K | −99% | $271.7M | |
| Q4 FY23 | $201.2M | +3353333% | $371.2M | |
| Q3 FY23 | $0 | −100% | $170M |
Against its peers
Companies in Biotechnology nearest CRISPR Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| CRSPCRISPR Therapeutics | $13.4M | −65% a year |
| KRYSKrystal Biotech | $440.5M | +23% a year |
| ADMAAdma Biologics | $512.3M | +8% a year |
| RGENRepligen | $785.1M | +16% a year |
| VCELVericel | $306.3M | +23% a year |
| TECHBIO-TECHNE | $1.2B | −0% a year |
| HALOHalozyme Therapeutics | $1.7B | +41% a year |
| NBIXNeurocrine Biosciences | $3.4B | +34% a year |
| EXELExelixis | $2.4B | +9% a year |
| INCYIncyte | $5.8B | +27% a year |
| UTHRUnited Therapeutics | $3.2B | +2% a year |
| Peer median | $1.4B |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on CRISPR Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.